KPTI Karyopharm Therapeutics Inc. Stock Quote

KPTI [NASD]

Index	-	P/E	-	EPS (ttm)	-2.76	Insider Own	9.66%	Shs Outstand	75.46M	Perf Week	3.11%
Market Cap	583.99M	Forward P/E	-	EPS next Y	-2.19	Insider Trans	-0.01%	Shs Float	68.25M	Perf Month	24.51%
Income	-206.20M	PEG	-	EPS next Q	-0.49	Inst Own	78.10%	Short Float	17.76%	Perf Quarter	53.90%
Sales	118.70M	P/S	4.92	EPS this Y	15.40%	Inst Trans	0.98%	Short Ratio	5.27	Perf Half Y	-6.33%
Book/sh	-1.67	P/B	-	EPS next Y	27.60%	ROA	-73.10%	Target Price	14.00	Perf Year	-45.13%
Cash/sh	2.90	P/C	2.86	EPS next 5Y	-	ROE	416.20%	52W Range	4.42 - 17.39	Perf YTD	28.77%
Dividend	-	P/FCF	-	EPS past 5Y	3.90%	ROI	-71.30%	52W High	-52.39%	Beta	-0.16
Dividend %	-	Quick Ratio	3.50	Sales past 5Y	236.60%	Gross Margin	96.90%	52W Low	87.33%	ATR	0.57
Employees	432	Current Ratio	3.50	Sales Q/Q	77.00%	Oper. Margin	-	RSI (14)	60.85	Volatility	8.58% 7.69%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	5.70%	Profit Margin	-	Rel Volume	1.05	Prev Close	7.73
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 03 BMO	Payout	-	Avg Volume	2.30M	Price	8.28
Recom	2.40	SMA20	12.28%	SMA50	13.98%	SMA200	7.94%	Volume	2,408,037	Change	7.12%

Nov-19-21

Resumed

Morgan Stanley

Equal-Weight

$27 → $10

Aug-06-21

Downgrade

SVB Leerink

Outperform → Mkt Perform

Aug-06-21

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$17 → $8

Aug-06-21

Downgrade

JP Morgan

Overweight → Neutral

Jul-02-20

Initiated

Morgan Stanley

Overweight

$34

Mar-04-20

Initiated

Barclays

Overweight

$30

Jan-17-20

Downgrade

Wedbush

Outperform → Neutral

Jul-23-19

Upgrade

JP Morgan

Neutral → Overweight

$8 → $16

Jul-05-19

Reiterated

Robert W. Baird

Outperform

$15 → $25

Jul-05-19

Reiterated

H.C. Wainwright

Buy

$29 → $32

Mar-01-19

Downgrade

JP Morgan

Overweight → Neutral

$21 → $7

Feb-28-19

Reiterated

BofA/Merrill

Underperform

$15 → $5

Feb-27-19

Downgrade

BofA/Merrill

Neutral → Underperform

$15 → $5

Jan-03-19

Upgrade

BofA/Merrill

Underperform → Neutral

Dec-03-18

Initiated

B. Riley FBR

Buy

$23

Nov-09-18

Upgrade

Wedbush

Neutral → Outperform

$19

May-24-18

Downgrade

Wedbush

Outperform → Neutral

$20 → $19

Apr-02-18

Resumed

Leerink Partners

Outperform

$19

Nov-15-17

Resumed

H.C. Wainwright

Buy

$23

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$14

Jan-21-22 07:00AM	Karyopharm to Present at B. Riley Securities Oncology Investor Conference PR Newswire +7.12%
Jan-10-22 07:05AM	Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer PR Newswire +9.92%
07:00AM	Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives PR Newswire
Jan-04-22 07:00AM	Karyopharm to Present at 40th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-03-22 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire +10.42%
Dec-21-21 08:39PM	Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories PR Newswire
03:09PM	Karyopharm, Menarini Ink Over $200M Licensing Pact For Selinexor In Europe, Other Territories Benzinga
08:51AM	Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories CNW Group
07:30AM	Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories PR Newswire
Dec-17-21 08:37AM	Karyopharm's Partner Antengene Receives Approval in China for XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma PR Newswire
Dec-11-21 12:00PM	Karyopharm Announces Presentation of Updated Phase 2 Selinexor Data in Patients with Myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition PR Newswire
Dec-06-21 04:05PM	Karyopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of Directors PR Newswire
07:00AM	Karyopharm Announces Dosing of First Patient in a New Phase 2 Study Evaluating Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis PR Newswire
Dec-02-21 07:00AM	Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer PR Newswire +8.82%
Dec-01-21 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
07:00AM	Karyopharm to Host Virtual Investor Day on December 8, 2021 PR Newswire
Nov-29-21 09:00AM	Implied Volatility Surging for Karyopharm (KPTI) Stock Options Zacks -5.78%
Nov-11-21 07:00AM	Karyopharm to Participate at Jefferies London Healthcare Conference PR Newswire
Nov-04-21 10:30AM	Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition PR Newswire
Nov-03-21 03:01PM	Karyopharm Therapeutics inc (KPTI) Q3 2021 Earnings Call Transcript Motley Fool +37.37%
08:25AM	Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM	Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights PR Newswire
Nov-01-21 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire +6.59%
Oct-27-21 07:00AM	Karyopharm to Report Third Quarter 2021 Financial Results on November 3, 2021 PR Newswire
Oct-25-21 03:01PM	Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-23-21 06:08AM	15 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors Insider Monkey
Oct-21-21 08:00AM	Karyopharm Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome PR Newswire
Oct-01-21 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Sep-07-21 07:00AM	Karyopharm Announces Upcoming Virtual Investor Conference Participation PR Newswire
Sep-01-21 07:00AM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Aug-20-21 11:16AM	Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options Zacks
Aug-13-21 09:16AM	Karyopharm Therapeutics Charts Are Bearish With a Capital B TheStreet.com
Aug-07-21 03:46AM	Analysts Just Made A Major Revision To Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Revenue Forecasts Simply Wall St.
Aug-05-21 08:00PM	Karyopharm Therapeutics inc (KPTI) Q2 2021 Earnings Call Transcript Motley Fool -24.17%
07:00AM	Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results PR Newswire
Aug-03-21 07:00AM	Karyopharm Announces Upcoming Virtual Investor Conference Participation PR Newswire -7.72%
Aug-02-21 07:00AM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jul-29-21 07:00AM	Karyopharm to Report Second Quarter 2021 Financial Results on August 5, 2021 PR Newswire
Jul-28-21 07:00AM	Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis PR Newswire
Jul-27-21 03:03PM	Analysts Estimate Karyopharm Therapeutics (KPTI) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-20-21 12:43AM	Karyopharm Therapeutics Inc (KPTI): Are Hedge Funds Right About This Stock? Insider Monkey
Jul-01-21 08:00AM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jun-24-21 07:00AM	Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million PR Newswire
Jun-09-21 01:49PM	Karyopharm Stock Is Trading Higher On Updated Eltanexor Data In Patients With Blood Disorder Benzinga +6.26%
07:00AM	Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress PR Newswire
Jun-08-21 08:00PM	Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS PR Newswire
04:01PM	Karyopharm Announces Key Changes to Its Commercial Leadership Team PR Newswire
Jun-03-21 07:00AM	Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets PR Newswire
Jun-02-21 07:00AM	Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma PR Newswire
Jun-01-21 04:01PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
May-26-21 08:00AM	Karyopharm to Participate at Jefferies 2021 Virtual Healthcare Conference PR Newswire
May-19-21 05:01PM	Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting PR Newswire
May-09-21 03:55AM	Some Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Analysts Just Made A Major Cut To Next Year's Estimates Simply Wall St.
May-04-21 08:00AM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire -10.17%
May-03-21 04:30PM	Karyopharm Therapeutics Inc (KPTI) Q1 2021 Earnings Call Transcript Motley Fool
08:25AM	Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:05AM	Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress PR Newswire
07:00AM	Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer PR Newswire
06:30AM	Karyopharm Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Apr-28-21 07:00AM	Karyopharm to Report First Quarter 2021 Financial Results on May 3, 2021 PR Newswire
Apr-26-21 07:00AM	Karyopharm Announces European Medicines Agency's Validation of its Type II Variation Marketing Authorization Application for NEXPOVIO® (selinexor) in Combination with Velcade® (bortezomib) and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma PR Newswire
Apr-19-21 07:00AM	Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology PR Newswire
Apr-14-21 03:33AM	Market Sentiment Around Loss-Making Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Simply Wall St.
Apr-06-21 06:19AM	Karyopharm Stock Is Trading Higher After China's NMPA Signs Off Early-Stage ATG-019 Study In Cancer Settings Benzinga -5.76%
Apr-01-21 08:00AM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Mar-29-21 02:27PM	Karyopharm's Selinexor Receives Conditional Approval In Europe For Type Of Blood Cancer Benzinga
12:49PM	Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma PR Newswire
Mar-01-21 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Feb-17-21 04:05PM	Karyopharm Announces Upcoming Virtual Investor Conference Participation PR Newswire
Feb-13-21 02:04AM	Analysts Have Lowered Expectations For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Its Latest Results Simply Wall St.
Feb-12-21 10:50PM	KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI Business Wire
02:58AM	Is Karyopharm Therapeutics (NASDAQ:KPTI) Weighed On By Its Debt Load? Simply Wall St.
Feb-11-21 02:30PM	Karyopharm Therapeutics Inc (KPTI) Q4 2020 Earnings Call Transcript Motley Fool
09:46AM	Recap: Karyopharm Therapeutics Q4 Earnings Benzinga
08:45AM	Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates Zacks
07:26AM	The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts Benzinga
07:00AM	Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress PR Newswire
06:30AM	Karyopharm Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-04-21 09:00AM	Karyopharm to Report Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021 PR Newswire
07:00AM	Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma PR Newswire
Feb-01-21 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jan-29-21 10:50PM	KARYOPHARM INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI PR Newswire
08:38AM	Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma PR Newswire
Jan-11-21 08:00AM	Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update PR Newswire -8.59%
Jan-04-21 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire +9.30%
07:00AM	Karyopharm to Present at 39th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-03-21 07:00PM	Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL PR Newswire
Dec-21-20 09:29AM	Karyopharm's (KPTI) Xpovio Gets FDA Nod for Second-Line Myeloma Zacks
Dec-20-20 07:00PM	Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy PR Newswire
Dec-18-20 10:50PM	KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI Business Wire +8.36%
10:44PM	Is KPTI A Good Stock To Buy According To Hedge Funds? Insider Monkey
11:30AM	Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy PR Newswire
Dec-15-20 07:00AM	Karyopharm Appoints Michael Mano as Senior Vice President, General Counsel and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Dec-14-20 02:14AM	Can You Imagine How Karyopharm Therapeutics' (NASDAQ:KPTI) Shareholders Feel About The 66% Share Price Increase? Simply Wall St.
Dec-11-20 11:08AM	Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma PR Newswire
Dec-07-20 04:05PM	Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting PR Newswire
01:30PM	Karyopharm Presents XPOVIO® (Selinexor) Data in Multiple Myeloma and Diffuse Large-B-Cell Lymphoma at the American Society of Hematology 2020 Annual Meeting PR Newswire
Dec-01-20 04:05PM	Karyopharm Announces Investor and Analyst Event at the American Society of Hematology 2020 Annual Meeting PR Newswire
07:00AM	Karyopharm Expands Board of Directors and Executive Leadership Team and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Nov-30-20 03:48AM	Wall Street Analysts See These 4 Stocks As Winners Moving Into December Benzinga +12.22%

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company's lead compound, XPOVIO (selinexor), is approved in the U.S. in various hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. Its NEXPOVIO (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission. In addition, the company's SINE compounds also show biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Further, it also has various investigational programs in clinical or preclinical development. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mitchener Stephen	SVP, Chief Business Officer	Dec 02	Sale	6.69	499	3,338	3,296	Dec 03 06:17 PM
Mitchener Stephen	SVP, Chief Business Officer	Jun 02	Sale	9.29	528	4,905	2,472	Jun 03 04:06 PM
Shah Jatin	EVP, Chief Medical Officer	May 07	Buy	8.60	23,250	199,992	131,802	May 11 08:58 AM
BOHLIN GAREN G	Director	May 06	Buy	7.82	4,000	31,280	4,000	May 10 07:57 PM
Shacham Sharon	President & CSO	Mar 18	Sale	12.39	4,000	49,553	714,826	Mar 23 07:50 AM
Kauffman Michael	Chief Executive Officer	Mar 18	Sale	12.39	4,000	49,553	714,826	Mar 23 07:48 AM
Frenkel Ran	EVP, Chief Dev. Officer	Feb 18	Sale	14.83	2,887	42,818	46,126	Feb 22 08:11 PM
Shah Jatin	EVP, Chief Medical Officer	Feb 18	Sale	14.83	1,186	17,590	51,791	Feb 22 08:12 PM
Shacham Sharon	President & CSO	Feb 18	Sale	14.83	9,495	140,822	575,126	Feb 22 08:10 PM
Shacham Sharon	President & CSO	Feb 18	Sale	14.83	9,495	140,822	776,452	Feb 22 08:10 PM
Kauffman Michael	Chief Executive Officer	Feb 18	Sale	14.83	9,495	140,822	776,452	Feb 22 08:09 PM
Kauffman Michael	Chief Executive Officer	Feb 18	Sale	14.83	9,495	140,822	575,126	Feb 22 08:09 PM
Lewis Tanya	EVP, Chief Reg. Affairs	Feb 11	Sale	15.52	2,046	31,752	4,143	Feb 17 06:49 PM
Shah Jatin	EVP, Chief Medical Officer	Feb 11	Sale	15.52	1,748	27,127	48,127	Feb 17 06:48 PM
Frenkel Ran	EVP, Chief Dev. Officer	Feb 11	Sale	15.52	2,046	31,752	39,338	Feb 17 06:47 PM
Shacham Sharon	President & CSO	Feb 11	Sale	15.52	6,601	102,441	562,821	Feb 17 06:45 PM
Shacham Sharon	President & CSO	Feb 11	Sale	15.52	6,642	103,077	764,147	Feb 17 06:45 PM
Mason Michael	SVP, CFO & Treasurer	Feb 11	Sale	15.52	2,858	44,354	5,292	Feb 17 06:46 PM
Kauffman Michael	Chief Executive Officer	Feb 11	Sale	15.52	6,642	103,077	764,147	Feb 17 06:44 PM
Kauffman Michael	Chief Executive Officer	Feb 11	Sale	15.52	6,601	102,441	562,821	Feb 17 06:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience